Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2019, Article ID 4230948, 7 pages
https://doi.org/10.1155/2019/4230948
Research Article

Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention

1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Department of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
2Xi’An Number One Hospital, Xi’an 710002, China
3Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China
4Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China

Correspondence should be addressed to Tong Liu; moc.621@codgnotuil and Guangping Li; moc.621@loidracjt_cit

Received 16 January 2019; Revised 17 June 2019; Accepted 25 June 2019; Published 2 September 2019

Academic Editor: Robert Chen

Copyright © 2019 Shuai Shao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Yeghiazarians, J. B. Braunstein, A. Askari, and P. H. Stone, “Unstable angina pectoris,” New England Journal of Medicine, vol. 342, no. 2, pp. 101–114, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. Wiviott and E. Braunwald, “Unstable angina and non-ST-segment elevation myocardial infarction: part 1. Initial evaluation and management and hospital care,” American Family Physician, vol. 70, pp. 525–532, 2004. View at Google Scholar
  3. A. P. Banning, A. Baumbach, D. Blackman et al., “Percutaneous coronary intervention in the UK: recommendations for good practice,” Heart, vol. 101, no. 3, pp. 1–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Gada, A. J. Kirtane, D. J. Kereiakes et al., “Meta-analysis of trials on mortality after percutaneous coronary intervention compared with medical therapy in patients with stable coronary heart disease and objective evidence of myocardial ischemia,” The American Journal of Cardiology, vol. 115, no. 9, pp. 1194–1199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Prati, F. Imola, P. Corvo et al., “The restart project: high-dose atorvastatin helps control restenosis after stenting procedures at high risk for restenosis. Results from aprospective study and a matched control group comparison,” EuroIntervention, vol. 3, no. 1, pp. 89–91, 2007. View at Publisher · View at Google Scholar
  6. P. Chrusciel, J. Rysz, and M. Banach, “Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease,” Drugs, vol. 74, no. 9, pp. 971–980, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Peng, M. Zhao, J. Wan, Q. Fang, D. Fang, and K. Li, “The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials,” International Journal of Cardiology, vol. 177, no. 3, pp. 780–785, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Rehberger-Likozar and M. Šebeštjen, “Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease,” Coronary Artery Disease, vol. 26, no. 8, pp. 651–656, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST elevation myocardial infarction): developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons: endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine,” Journal of the American College of Cardiology, vol. 50, pp. 1–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines,” Circulation, vol. 127, pp. 663–828, 2013. View at Google Scholar
  11. G. A. Roth, M. D. Huffman, A. E. Moran et al., “Global and regional patterns in cardiovascular mortality from 1990 to 2013,” Circulation, vol. 132, no. 17, pp. 1667–1678, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C. L. Grines, K. J. Harjai, and T. L. Schreiber, “Percutaneous coronary intervention: 2015 in review,” Journal of Interventional Cardiology, vol. 29, no. 1, pp. 11–26, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. G. G. Babu, J. M. Walker, D. M. Yellon, and D. J. Hausenloy, “Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection,” European Heart Journal, vol. 32, pp. 23–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. F. J. P. Bernink, L. Timmers, A. M. Beek et al., “Progression in attenuating myocardial reperfusion injury: an overview,” International Journal of Cardiology, vol. 170, no. 3, pp. 261–269, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Schreiber, B. Specht, and M. Pelsers, “Recombinant human heart type fatty acid binding protein as standard immunochemical assays,” Clinical Chemistry and Laboratory Medicine, vol. 36, pp. 283–288, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Ruzgar, A. K. Bilge, Z. Bugra et al., “The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band,” Heart and Vessels, vol. 21, no. 5, pp. 309–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Shabaiek, N. E.-H. Ismael, S. Elsheikh, and H. A. Amin, “Role of cardiac myocytes heart fatty acid binding protein depletion (H-FABP) in early myocardial infarction in human heart,” Open Access Macedonian Journal of Medical Sciences, vol. 4, no. 1, pp. 17–21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. C. Glatz and J. Storch, “Unravelling the significance of cellular fatty acid binding proteins,” Current Opinion in Lipidology, vol. 12, no. 3, pp. 267–274, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. C. P. Y. Chan, W. S. Cheng, J. F. C. Glatz, A. Hempel, R. Renneberg, and J. E. Sanderson, “A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein,” Zeitschrift für Kardiologie, vol. 93, no. 5, pp. 388–397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Nightingale and D. Cutler, “The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story,” Journal of Thrombosis and Haemostasis, vol. 11, pp. 192–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Lenting, O. D. Christophe, and C. V. Denis, “Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends,” Blood, vol. 125, no. 13, pp. 2019–2028, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Cambronero, J. A. Vilchez, A. Garcia-Honrubia et al., “Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy,” Thrombosis Research, vol. 126, pp. 46–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Paulus, C. Jennewein, and K. Zacharowski, “Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?” Biomarkers, vol. 16, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro, “Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect,” European Heart Journal, vol. 28, no. 9, pp. 1102–1108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Hao, H. Du, W. W. Li et al., “Effects of atorvastatin combined with trimetazidine on myocardial injury and inflammatory mediator in unstable angina patients during perioperative of percutaneous coronary intervention,” European Review for Medical and Pharmacological Sciences, vol. 19, pp. 4642–4646, 2015. View at Google Scholar
  26. Y. Zhang, X. J. Ma, and D. Z. Shi, “Effect of trimetazidine in patients undergoing percutaneous coronary intervention: a meta-analysis,” PLoS One, vol. 10, no. 9, Article ID e0137775, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. P. F. Kantor, A. Lucien, R. Kozak, and G. D. Lopaschuk, “The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme a tiolase,” Circulation Research, vol. 86, no. 5, pp. 580–588, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Tabbi-Anneni, A. Lucien, and A. Grynberg, “Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequences in alpha-adrenergic signaling,” Fundamental and Clinical Pharmacology, vol. 17, no. 1, pp. 51–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Kuralay, E. Altekin, A. S. Yazlar, B. Onvural, and O. Goldeli, “Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine,” The Tohoku Journal of Experimental Medicine, vol. 208, no. 3, pp. 203–212, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. D. H. Kazmi, A. Kapoor, A. Sinha et al., “Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury,” Indian Heart Journal, vol. 70, no. 3, pp. s365–s371, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Lampropoulos, A. Megalou, G. Bazoukis, G. Tse, and A. Manolis, “Pre-loading therapy with statins in patients with angina and acute coronary syndromes undergoing PCI,” Journal of Interventional Cardiology, vol. 30, no. 6, pp. 507–513, 2017. View at Publisher · View at Google Scholar · View at Scopus